W. Umstead John - Mar 15, 2023 Form 3 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role
Chief Financial Officer
Signature
/s/ James Stillman Hanson, attorney-in-fact
Stock symbol
GTHX
Transactions as of
Mar 15, 2023
Transactions value $
$0
Form type
3
Date filed
3/17/2023, 04:10 PM
Next filing
May 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GTHX Common Stock 8.89K Mar 15, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GTHX Stock Options (Right to buy) Mar 15, 2023 Common Stock 10K $41.48 Direct
holding GTHX Stock Options (Right to buy) Mar 15, 2023 Common Stock 2K $30.46 Direct F2
holding GTHX Stock Options (Right to buy) Mar 15, 2023 Common Stock 6.6K $21.08 Direct F3
holding GTHX Stock Options (Right to buy) Mar 15, 2023 Common Stock 2.55K $18.07 Direct F4
holding GTHX Stock Options (Right to buy) Mar 15, 2023 Common Stock 6.1K $10.69 Direct F5
holding GTHX Stock Options (Right to buy) Mar 15, 2023 Common Stock 6K $5.73 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents (i) 2,036 shares of common stock; (ii) 850 restricted stock units ("RSUs") from award granted on January 4, 2021; (iii) 3,000 RSUs from award granted on January 3, 2022; and (iv) 3,000 RSUs from award granted on January 3, 2023.
F2 The shares underlying this option vest as to 25% of the shares on July 1, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The option was granted on July 1, 2019.
F3 The shares underlying this option vest as to 25% of the shares on February 6, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The option was granted on February 6, 2020.
F4 The shares underlying this option vest as to 25% of the shares on January 4, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The option was granted on January 4, 2021.
F5 The shares underlying this option vest as to 25% of the shares on January 3, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The option was granted on January 3, 2022.
F6 The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The option was granted on January 3, 2023.